Identification of the site of glycation of human insulin.
This study evaluates the nature of glycated human insulin formed following exposure to hyperglycemic conditions in vitro. Glycated insulin was purified by RP-HPLC and its molecular mass (5971.3 Da) determined by plasma desorption mass spectrometry (MS). The difference in mass (163.7 Da) from nonglycated insulin (5807.6 Da) corresponds to a single reduced glucose (glucitol) residue. Following reduction of insulin disulfide bridges, MS confirmed that the B-chain was glycated. Enzymatic digestions with trypsin, endoproteinase Glu-C, and thermolysin, followed by RP-HPLC and identification of fragments by MS, localized glycation to the B-chain (1-5) region. Electrospray tandem MS identified the site of glycation as the B-chain NH2-terminal Phe1 residue. This was confirmed by automated Edman degradation with glycated human insulin.
O'Harte
F P
FP
School of Biomedical Sciences, University of Ulster, Coleraine, N. Ireland, UK.
Højrup
P
P
Barnett
C R
CR
Flatt
P R
PR
D000595:Amino Acid Sequence; D001665:Binding Sites; D002851:Chromatography, High Pressure Liquid; D006031:Glycosylation; D006801:Humans; D006943:Hyperglycemia / Q000378:metabolism; D066298:In Vitro Techniques; D007328:Insulin / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000378:metabolism*; D015394:Molecular Structure; D010446:Peptide Fragments / Q000737:chemistry / Q000302:isolation & purification; D011487:Protein Conformation
D007328:Insulin; D010446:Peptide Fragments; C039522:insulin, glycosylated